Johnson & Johnson is a global American pharmaceutical and consumer goods company with headquarters in New Brunswick, New Jersey. The company is listed in the Dow Jones Industrial Average.
According to Johnson & Johnson's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 22.6885. At the end of 2021 the company had a P/E ratio of 21.6.
Year | P/E ratio | Change |
---|---|---|
2021 | 21.6 | -23.35% |
2020 | 28.2 | 33.07% |
2019 | 21.2 | -6.74% |
2018 | 22.7 | -92.46% |
2017 | 301 | 1460.23% |
2016 | 19.3 | 4.46% |
2015 | 18.5 | 2.49% |
2014 | 18.0 | -3.32% |
2013 | 18.6 | 4.62% |
2012 | 17.8 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Novartis NVS | 28.8 | 27.10% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 7.28 | -67.92% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | 23.6 | 3.92% | ๐บ๐ธ USA |
![]() Medtronic MDT | 26.4 | 16.34% | ๐ฎ๐ช Ireland |
![]() Eli Lilly LLY | 51.2 | 125.54% | ๐บ๐ธ USA |
![]() Sanofi SNY | 19.1 | -15.70% | ๐ซ๐ท France |
![]() Gilead Sciences GILD | 22.6 | -0.37% | ๐บ๐ธ USA |
![]() Stryker Corporation SYK | 45.8 | 101.72% | ๐บ๐ธ USA |
![]() Merck MRK | 18.6 | -18.19% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 4.50 | -80.18% | ๐ฌ๐ง UK |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.